Baghdassarian N, Catallo R, Mahly M A, Ffrench P, Chizat F, Bryon P A, Ffrench M
Faculté de Médecine, Laboratoire de Cytologie Analytique, Lyon, France.
Exp Cell Res. 1998 May 1;240(2):263-73. doi: 10.1006/excr.1998.3942.
In order to analyze dexamethasone effects on peripheral blood lymphocyte proliferation, we defined various experimental conditions: dexamethasone introduced (i) at the time of phytohemagglutinin stimulation, (ii) 48 h after the beginning of phytohemagglutinin stimulation, and (iii) on unstimulated lymphocytes. In stimulated lymphocytes, we observed an early G1 accumulation (P < 0.005), a delayed increase in the duration of S-phase (P < 0.03), and a consequent increase in cell-cycle duration. The expression of several cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors (CKIs) was modified. Cyclin D3, CDK4, and CDK6 involved in G1-phase control were significantly decreased under dexamethasone treatment whatever the level of stimulation of lymphocytes (stimulated or unstimulated PBL). Cyclin E and CDK2, acting in G1/ S-phase transition and S-phase regulation, decreased in stimulated lymphocytes before any modification of S-phase (P < 0.002). The expression of CKIs, mainly of p27Kip1, appeared to vary with the degree of cell stimulation: a decrease was observed on treated unstimulated lymphocytes, while p27Kip1 increased in dexamethasone-treated cells during stimulation. Our results indicate sequential modifications of the cell-cycle regulation by dexamethasone starting with an action on G1 followed by S-phase control modifications. The protein analysis pinpoints the major complexes concerned: CDK4 and CDK6/cyclin D are mainly involved in G1-phase modifications, while CDK2 and its partner, cyclin E, might be specifically involved in the lengthening of S-phase. The variations observed for p27Kip1 might amplify the functional effects of dexamethasone on kinasic complexes.
为了分析地塞米松对外周血淋巴细胞增殖的影响,我们定义了各种实验条件:地塞米松在(i)植物血凝素刺激时引入,(ii)植物血凝素刺激开始后48小时引入,以及(iii)对未刺激的淋巴细胞引入。在受刺激的淋巴细胞中,我们观察到早期G1期积累(P<0.005),S期持续时间延迟增加(P<0.03),以及细胞周期持续时间随之增加。几种细胞周期蛋白、细胞周期蛋白依赖性激酶(CDK)和CDK抑制剂(CKI)的表达发生了改变。无论淋巴细胞的刺激水平如何(刺激或未刺激的外周血淋巴细胞),在地塞米松治疗下,参与G1期控制的细胞周期蛋白D3、CDK4和CDK6均显著降低。在S期发生任何改变之前,参与G1/S期转换和S期调节的细胞周期蛋白E和CDK2在受刺激的淋巴细胞中减少(P<0.002)。CKI的表达,主要是p27Kip1,似乎随细胞刺激程度而变化:在处理的未刺激淋巴细胞中观察到减少,而在刺激期间地塞米松处理的细胞中p27Kip1增加。我们的结果表明,地塞米松对细胞周期调节的影响是连续的,首先作用于G1期,随后是S期控制的改变。蛋白质分析确定了主要相关复合物:CDK4和CDK6/细胞周期蛋白D主要参与G1期改变,而CDK2及其伴侣细胞周期蛋白E可能特别参与S期延长。观察到的p27Kip1变化可能会放大地塞米松对激酶复合物的功能影响。